

Patent Application  
Attorney Docket No. PC10299A

*Suppl  
Amat  
9/B  
Linda  
10/18/01*

I hereby certify that this correspondence has been transmitted via facsimile to Examiner Devi in Group Art Unit 1645 of the United States Patent and Trademark Office at facsimile number (703) 308-4242 on this 17<sup>th</sup> day of October, 2001, addressed to: Commissioner for Patents, Washington, D.C. 20231.

By \_\_\_\_\_

(Signature of person transmitting and mailing)

(Typed or printed name of person)

BY TELEFACSIMILE: (703) 308-4242

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: David S. Roberts, et al. :

APPLICATION NO.: 09/489,711

: Examiner: Sarvamangala Jn Devi

FILING DATE: January 24, 2000

: Group Art Unit: 1645

TITLE: ERYSIPELOTHRIX RHUSIOPATHIAE /  
ANTIGENS AND VACCINE  
COMPOSITIONS**BY FACSIMILE**Commissioner for Patents  
Washington, D.C. 20231**OFFICIAL**

Sir:

**AMENDMENT IN RESPONSE TO OCTOBER 15, 2001 TELEPHONE INTERVIEW**

This Amendment is submitted in response to the October 13, 2001 Telephone Interview between applicants' undersigned attorney and Examiner Devi, the Examiner to whom the above-identified patent application has been reassigned for Telephone Interview, please amend the subject application as follows:

**In the Claims:**

Please cancel claims 6, 7, 9, 10 and 11.

Please add the following claims 12-22:

**CLEAN COPY – PLEASE ENTER:**

*Sub  
D  
B*

12. An antigen composition comprising a fluid fraction from an *E. rhusiopathiae* culture and a stabilizing agent.

13. The antigen composition of Claim 12, wherein said stabilizing agent is a metal hydroxide, a metal phosphate, an aluminum hydroxide gel, an aluminum phosphate gel, a calcium phosphate gel, a zinc hydroxide/calcium hydroxide gel or an alum.

14. The antigen composition of Claim 12, wherein said *E. rhusiopathiae* culture